Loading...
•
Dec 31, 2021
CorMedix Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
CorMedix reported a net loss of $7.8 million, or $0.20 per share, for the fourth quarter of 2021, compared to a net loss of $6.1 million, or $0.19 per share, in the fourth quarter of 2020. The increase in net loss was primarily driven by increases in costs related to the manufacturing of DefenCath prior to its potential marketing approval and non-cash charges for stock-based compensation.
FDA accepted for filing of DefenCath resubmission.
The CorMedix team is working hard to lay the groundwork for a potential commercial launch of DefenCath.
Net loss for the fourth quarter of 2021 was $7.8 million, or $0.20 per share.
Total cash on hand and short-term investments as of December 31, 2021 amounted to $65.5 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...